Newly Appointed Head of Regenerative Medicine At Shire Plans Rapid Growth For The Division
This article was originally published in The Pink Sheet Daily
Jeff Jonas takes over Shire’s newly formed Regenerative Medicine business with plans for rapid growth, replacing Advanced BioHealing’s Kevin Rakin in the role.
You may also be interested in...
The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.
The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.
The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.